AlveoGene’s Mission is to transform respiratory disease outcomes using inhaled gene therapy.

Our InGenuiTy® platform enables us to deliver our proprietary self-inactivating lentiviral vector based products directly to the lung via nebulisation treating disease locally, efficiently, and safely where it’s clinical impact and patient benefit can be the greatest.

We focus on respiratory diseases of high value and unmet medical need, developing first-in-class and best-in-class products including Alpha-1 Antitrypsin Deficiency (AATD), Neonatal Profound Surfactant Protein Deficiencies (SP-B and ABCA3), and Idiopathic pulmonary Fibrosis (IPF).

AlveoGene’s Executive Chair David Hipkiss and one of our Founders Professor Uta Griesenbach will be attending the event and meeting partners, collaborators and investors alike.

Professor Griesenbach will also be giving a presentation entitled ‘Gene Therapy for Rare Respiratory Diseases’ on Tuesday, March 19, 2024 5:10 PM to 5:30 PM in Gene Therapy Track 7

We look forward to seeing you in London.

For for more information or to arrange a meeting please email us at [email protected]